Academic literature on the topic 'Papillomavirus humain (HPV)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Papillomavirus humain (HPV).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Papillomavirus humain (HPV)":
Ouedraogo, Rogomenoma Alice, Théodora Mahoukèdè Zohoncon, Abdoul Karim Ouattara, and Jacques Simpore. "Prédominance du papillomavirus humain 56 dans une sous-population de femmes sexuellement actives à Garango, Centre-Est, Burkina Faso." Journal of Applied Biosciences 150 (June 30, 2020): 15499–509. http://dx.doi.org/10.35759/jabs.150.10.
Gavillon, N., H. Vervaet, E. Derniaux, P. Terrosi, O. Graesslin, and C. Quereux. "Papillomavirus humain (HPV) : comment ai-je attrapé ça ?" Gynécologie Obstétrique & Fertilité 38, no. 3 (March 2010): 199–204. http://dx.doi.org/10.1016/j.gyobfe.2010.01.003.
Ezebialu, C. U., I. U. Ezebialu, and C. C. Ezenyeaku. "Persistence of cervical human papillomavirus infection among cohort of women in Awka, Nigeria." African Journal of Clinical and Experimental Microbiology 22, no. 3 (July 2, 2021): 344–51. http://dx.doi.org/10.4314/ajcem.v22i3.5.
Manus, Jean-Marie. "Brève : Vaccin à papillomavirus humain (HPV) pour filles et garçons." Revue Francophone des Laboratoires 2021, no. 529 (February 2021): 19. http://dx.doi.org/10.1016/s1773-035x(21)00026-5.
Macdonald, Liane, Shelley Deeks, and Carolyn Doyle. "A Public Health Perspective on HPV Vaccination: Response to The HPV Vaccination Campaign: A Project of Moral Regulation in an Era of Biopolitics." Canadian Journal of Sociology 35, no. 4 (September 28, 2010): 627–32. http://dx.doi.org/10.29173/cjs8977.
Oumara, M., S. Guede, Abdou A. Issa, Garba S. Oumarou, Diaouga H. Soumana, Lankoande Z. Salifou, Yacouba M. Chaibou, R. M. Garba, and M. Nayama. "Epidémiologie et génotypage du papillomavirus humain au Niger : A propos de 30 cas au Centre National Santé de la Reproduction de Niamey." Journal de la Recherche Scientifique de l’Université de Lomé 26, no. 1 (April 18, 2024): 177–86. http://dx.doi.org/10.4314/jrsul.v26i1.24.
Perrin, Andry. "Vaccination contre le papillomavirus humain (HPV) chez le sujet masculin : évidence et pratique." Revue Médicale Suisse 15, no. 673 (2019): 2202–4. http://dx.doi.org/10.53738/revmed.2019.15.673.2202.
Farge, G., E. Guyot, M. Belhassen, M. Bérard, F. Jacoud, L. Bensimon, G. De pouvourville, and J. Baldauf. "Couverture vaccinale contre le papillomavirus humain (HPV) chez les adolescents français: étude PAPILLON." Gynécologie Obstétrique Fertilité & Sénologie 52, no. 5 (May 2024): 349. http://dx.doi.org/10.1016/j.gofs.2024.03.016.
Guyot, E., G. Farge, M. Belhassen, M. Berard, F. Jacoud, L. Bensimon, G. de Pouvourville, and J.-J. Baldauf. "Couverture vaccinale contre le papillomavirus humain (HPV) chez les adolescents français - Étude PAPILLON." Journal of Epidemiology and Population Health 72 (March 2024): 202216. http://dx.doi.org/10.1016/j.jeph.2024.202216.
Dib, Fadia, Gwenn Menvielle, and Pierre Chauvin. "Tous égaux face aux papillomavirus ? L’infection et la vaccination HPV au prisme des inégalités sociales de santé." Questions de santé publique, no. 38 (November 2019): 1–8. http://dx.doi.org/10.1051/qsp/2019038.
Dissertations / Theses on the topic "Papillomavirus humain (HPV)":
Olivera-Botello, Gustavo. "Modélisation numérique des aspects immunologiques de la réaction à l’infection à HPV et de la vaccination anti-HPV par Gardasil®." Thesis, Lyon 1, 2011. http://www.theses.fr/2011LYO10038/document.
Two prophylactic vaccines have demonstrated to prevent infections with the human papillomavirus (HPV). Thus, they have been in the market for the last four years, or so. The three main objectives of the present project were: i) to study in-silico the immunogenicity of one of these vaccines (Gardasil®); ii) to study in-silico the natural history of an HPV infection, and iii) to assess in-silico the potential of the following therapeutic hypothesis : the intramuscular administration of Gardasil® to patients already suffering from a recurrent respiratory papillomatosis would result in a better prognosis thanks to the fact that the HPV-specific immunoglobulins that would bathe the affected tissue would impede the virus to complete its life cycle and, therefore, the disease to progress. The main conclusions are: i) according to our simulations, the minimum serum IgG titer required for hampering the progression of a recurrent respiratory papillomatosis would be 200 mMU/mL ; ii) in order to keep, within a time window of ten years, the anti-HPV IgG titer over the just-mentioned therapeutic-effect threshold, the biggest possible fraction of time and through the administration of the smallest possible number of booster doses, it would be necessary, according to our simulations, to adopt the following vaccination schedule: the basic three doses (at months 0, 2 and 6), followed by three successive booster doses, every six months, until reaching the 24th month, followed by a late final booster dose, 18 months later. iii) incidentally, it would seem to be inappropriate, according to our simulations, to modify the original initial vaccination schedule (at months 0, 2 and 6)
Bernard, Xavier. "Stabilisation de p53 et rôle du kinome humain dans l'oncogenèse HPV." Strasbourg, 2010. http://www.theses.fr/2010STRA6223.
Third leading cause of cancer death in women, cervical carcinomas are associated in 99. 7% of cases with infection of human papillomavirus (HPV types 16 and 18 mostly). The oncogenic effect of these HPV is mainly caused by the integration of genes encoding two viral oncoproteins, E6 and E7 into the genome of infected cells. Specific inhibition of the E6 oncoprotein is a major therapeutic challenge. Indeed, inhibition of E6 leads to a restoration of p53 protein and induces the orientation of the cancer cells to senescence or apoptosis. However, the development of new therapeutic strategies requires an understanding of the carcinogenesis mechanisms in order to discover new targets and enable the development of effective strategies. It is within this scientific context that I entered my thesis project based on the molecular mechanisms dissection of the p53 protein degradation mediated by E6. For that, we articulated our work around two lines of research: (i) determination of the residues of p53 involved in the binding site with E6 of "high risk" HPV, responsible for the degradation of p53; (ii) identification of kinases involve in the p53 degradation in HPV transformed cells. This work demonstrated the importance of the conformation of the p53 core domain in the binding with the oncoprotein E6, by the structure / function studies of mutant p53. In addition, we have highlighted the role of the pseudo-kinase NRBP1 in the regulation of p53 in HPV transformed cells, via the NF-kB pathway
Mourareau, Céline. "Bio-CAD - Etude de biomarqueurs de progression tumorale dans les cancers des voies aéro-digestives supérieures en fonction de leur statut HPV." Thesis, Reims, 2016. http://www.theses.fr/2016REIMS029/document.
Each year, 610,000 cancers are diagnosed worldwide attributed to high risk human papillomavirus (HR-HPV) infection. Although head and neck squamous cell carcinoma (HNSCC) is mainly associated with tobacco and/or alcohol consumption, 20 to 25% are caused by HPV infection, particularly HPV type 16. Although patients with HPV+ tumors present a better overall survival, they are diagnosed with more lymph node metastasis than HPV-negative patients.Through a study of HNSCC derived cell lines, we showed that all HPV-positives cell lines harbored HPV genome integration through host genome, with different integration profiles. Cell lines identified as good HPV+ and HPV- tumors models are UPCI:SCC090 and FaDu respectively. The first one by its migratory and proliferative properties, the second through its poor aggressiveness and mutation of p53 cellular gene.In a study on a retrospective series of oropharyngeal carcinomas with surgical resection, 6 out of 40 cancers shown HPV16 active infection (expressing E6*I mRNA). We studied epithelial-to-mesenchymal transition (EMT) markers on this oropharyngeal cancers, according to HPV status. We found a larger loss of epithelial marker E-cadherin in HPV+ group and loss of this marker is associated with a worse overall survival.We showed that HPV and EMT status seem to be two independent factors that could combine differently to define different prognostic levels
Bonneault, Mélanie. "Modélisation dynamique des infections et co-infections génitales à papillomavirus humain (HPV) et de l’impact à long terme de la vaccination anti-HPV." Thesis, université Paris-Saclay, 2021. http://www.theses.fr/2021UPASR002.
Genital human papillomavirus (HPV) infection affects nearly one-third of people under the age of 25 years from the start of their sexual activity. Generally asymptomatic, it can lead to the development of cancerous lesions. Among the forty or so HPV genotypes transmitted via the genital tract, about fifteen have been evaluated as oncogenic and causal agents of cervical cancer. Two vaccines offered to young girls in France since 2007 target the two HPV genotypes most at risk of cervical cancer. As these vaccines only include a fraction of the HPV genotypes, the evolution of the prevalences of infection and co-infection remains uncertain. The aim of this thesis is to better understand the impact of interactions between HPV genotypes during intra-host co-infections on the evolution of the prevalences of vaccine (V) and non-vaccine (NV) genotypes. To meet this objective, this work is based on the development of an individual-based model that makes it possible to reproduce both the heterogeneity of sexual behaviour and the transmission dynamics of V and NV genotypes as functions of age. A first part of this thesis presents a detailed description of this stochastic model and its validation on survey data. This model assumes that the interaction between genotypes results in the reduction (competition) or extension (synergy) of the duration of infection by an NV genotype in the event of prior infection by a V genotype. Calibration of transmission parameters for various interaction strengths shows that several of them are compatible with pre-vaccine epidemiological data on infection and co-infection. In the simulations, after introduction of vaccination into the population, we observe that the prevalence of NV genotypes increases in the case of competition and decreases in the case of synergy, especially when the interaction is strong. In the event of competition, the increase in the prevalence of NV could lead to a slight decrease or even an increase in the overall prevalence of all genotypes despite vaccination. The second part aims to explore, through a simulation study, how the introduction of vaccination modifies the spread of infection in the contact network. The simulations highlight variations in NV prevalence before and after vaccination which are more marked in less active individuals. In the third part, the model is used to emulate epidemiological studies in order to determine the conditions (number of subjects, time after the introduction of the vaccine) necessary to detect a decrease or increase in HPV prevalences following vaccine introduction in the population. A systematic review of the literature reveals two observational study designs comparing the prevalences of infection either in two populations in the pre- and post-vaccination eras, or in vaccinated and unvaccinated people in the post-vaccination era. The results obtained suggest that the studies published to date, regardless of the design, lack statistical power to detect variation in NV prevalence. Based on the development of a model validated to reproduce realistic sexual behaviours and prevalences of HPV infection, this thesis work contributes to the improvement of epidemiological knowledge on HPV infections and co-infections and allows us to anticipate the impact of vaccine prevention measures on the prevalence of HPV infection
Fleury, Maxime Jean Jules. "Identification des épitopes inducteurs d'anticorps neutralisants de la protéine majeure de capside des papillomavirus humain de type 16 et 31." Tours, 2007. http://www.theses.fr/2007TOUR3309.
Human papillomaviruses (HPV) are the ethiologic agent of cervix cancer. Virus like particles (VLP) can be obteined by expressing capsid protein into eucaryotic systems. Those VLP have virions similar epitopes and can transfert reporter genes. The aim of this study was to identify the L1 protein epitopes of HPV 16 and 31 using monoclonal antibodies, L1 protein mutants, peptides sets, BIACORE and Bacterial display. Presence of HPV 16 major epitope and overlapping epitopes inducing neutralizing antibodies and cross-neutralizing antibodies was confirmed into the FG loop. The results show that the epitopes which induce neutralizing antibodies could be overlapping and on the FG loop of the HPV 31. Immunogenicless vector derived from HPV 16 were obteined by replacement of the FG loop of type 16 by type 31. HPV 31 pseudovirions were produced in mammalian cells to developp more sensitive neutralizing antibodies assay
Olivera-Botello, Gustavo. "Modélisation numérique des aspects immunologiques de la réaction à l'infection à HPV et de la vaccination anti-HPV par Gardasil®." Phd thesis, Université Claude Bernard - Lyon I, 2011. http://tel.archives-ouvertes.fr/tel-00846182.
Tang, Alexandre. "Rôle des lymphocytes B dans l'immunité anti-tumorale dans un modèle murin de cancer lié au papillomavirus humain (HPV)." Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCC248.
Enhancing ante-tumor immunity and preventing tumor escape are efficient strategies to increase the efficacy of therapeutic cancer vaccines. However, the treatment of advanced tumors remains difficult, mainly due to the immunosuppressive tumor microenvironment. Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) have been extensively studied and their role in suppressing tumor immunity is now well established. In contrast, the role of B lymphocytes in tumor immunity remains unclear, since B cells can promote tumor immunity or display regulatory functions to control excessive inflammation, mainly through IL-10 secretion. Here, we demonstrate in a mouse model of HPV-related cancer that B cells play a detrimental role in anti-tumor immunity and participate in tumor promotion. Indeed, in B cell-deficient MuMT mice, the tumor growth was impaired and tumor rejection occurred due to a strong T cell dependent anti-tumor response. We show that B cells expressing PD-L1, CD39 and Ly6A/E markers accumulate in the tumor draining lymph node (dLN) which can directly impact T cell immunity. This inhibition is IL-10 independent since B cells from tumor-bearing mice did not show an increased ability to secrete IL-10 and deficiency in IL-10 production did not impair tumor growth. Furthermore, genetic analysis based on Single Nucleotide Polymorphisms (SNPs) also evidenced a relation between tumor rejection in MuMT mice and reactive oxygen species production and NK cell activity. Our results suggest that targeting B cell populations could enhance anti-tumor response and improve the efficacy of therapeutic cancer vaccines
Mandy, Muller. "La cartographie comparative des interactions E2-hôte révèle de nouveaux rôles de E2 dans la pathogénie associée aux papillomavirus humain." Phd thesis, Université Paris-Diderot - Paris VII, 2013. http://tel.archives-ouvertes.fr/tel-00881786.
Sandoval, Federico. "Optimisation d’un vaccin thérapeutique contre les tumeurs des voies aérodigestives supérieures associées au virus de papilloma humain (HPV) : Mise en évidence du rôle de la compartimentalisation de la réponse immunitaire antitumorale." Thesis, Paris 5, 2012. http://www.theses.fr/2012PA05T012.
Recent clinical trials have shown the therapeutic benefits of new promising immunotherapies (Sipoleucel T for prostate cancer, Ipilimumab in melanoma…). But by far, the majority of cancer vaccine clinical trials have shown modest clinical effects on cancer patients, contrasting with results found in preclinical models. Those preclinical models of cancer rely on subcutaneous grafts of tumor cells which do not mimic the true anatomic location of tumor lesions. In addition, in most cases cancer vaccines are administrated by systemic route, eliciting systemic antitumor responses and therapeutic effects. The antitumor response elicited by those vaccine strategies at the local environment of tumor location and their antitumor effect on orthotopic tumor models has not yet been addressed in preclinical cancer models. Since the majority of human tumors develop at mucosal surfaces, we addressed the question of the effect of the immunization route in the induction of local mucosal antitumor CD8+T cell responses by comparing a systemic intramuscular (i.m.) and intranasal (i.n.) route of administration of cancer vaccine. This vaccine consists of a non-replicative vaccine strategy that targets tumor antigen in vivo to dendritic cells developed at our laboratory and composed of the B subunit of the Shiga toxin (STxB) associated to a tumor antigen (E7 protein of HPV16). We also analyzed the antitumor effect of these vaccinations on two mucosal orthotopic tumor models of head and neck and lung cancer expressing the E7 antigen. We found that intranasal vaccination induced stronger specific CD8+T cell responses and antitumor effects at mucosal sites than systemic immunization, and, that mucosal vaccination induced a mucosal imprinting phenotype on mucosal derived antigen specific T cells as they expressed the mucosal integrins CD103 and CD49a, as opposed to systemic specific CD8+T cells or tumor infiltrating T cells in subcutaneous tumors. Inhibition of CD49a reduced the antitumor efficacy of the nasal vaccine and the number of tumor infiltrating CD8+T cells on orthotopic mucosal tumors. Our results showed that systemic antigen-specific T cell responses as typically assessed did not predict the quality of local mucosal immune response. Our observations provide direct evidence for the compartmentalization of mucosal tumor immunity, a critical finding for the rational design of better cancer vaccines
Desaintes, Christian. "Etude de la régulation transcriptionnelle par la protéine E6 du papillomavirus humain de type 16(HPV 16), et par la protéine cellulaire "suppresseur de tumeur" p53." Doctoral thesis, Universite Libre de Bruxelles, 1994. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/212697.
Books on the topic "Papillomavirus humain (HPV)":
Nardo, Don. Human papillomavirus (HPV). Detroit: Lucent Books, 2007.
Dizon, Don S. Questions & answers about human papilloma virus (HPV). Sudbury, Mass: Jones and Bartlett Publishers, 2011.
United States. Indian Health Service. Genital human papillomavirus (HPV). Atlanta, Ga.]: Dept. of Health and Human Services, Centers for Disease Control and Prevention, Indian Health Service, 2011.
Syrjänen, Kari J. Human papillomavirus (HPV) involvement in esophageal carcinogenesis. New York: Nova Biomedical Books, 2010.
Dizon, Don S. Questions & answers about human papilloma virus (HPV). Sudbury, Mass: Jones and Bartlett Publishers, 2011.
Miller, Daniel L., and M. Sharon Stack, eds. Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21100-8.
Syrjänen, Kari J. Human papillomavirus (HPV) involvement in esophageal carcinogensis. Hauppauge, N.Y: Nova Science, 2009.
Zavaleta, Leticia Rocha. Immune response to human papillomavirus (HPV) in cervical cancer and cervical intraepithelial neoplasia. Manchester: University of Manchester, 1996.
Kwaśniewska, Anna. Infekcje wirusem brodawczaka ludzkiego (HPV-Human Papillomavirus): Surowiczy poziom antyoksydantow oraz rola zywienia w dysplazji szyjki macicy. Poznań: Wydawnictwo Naukowe Uniwersytet im. Adama Mickiewicza w Poznaniu, 1998.
Thomas, David Peter. Studies on tumourigenesis in transgenic mice expressing the early region genes of human papillomavirus type 16 (HPV-16). Birmingham: University of Birmingham, 1996.
Book chapters on the topic "Papillomavirus humain (HPV)":
Thompson, Amelia B., and Lisa C. Flowers. "Human Papillomavirus (HPV)." In Sexually Transmitted Infections in Adolescence and Young Adulthood, 279–97. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-20491-4_18.
Strickland, Amanda, and Gabriela Blanco. "Human Papillomavirus (HPV)." In Dermatology Atlas for Skin of Color, 201–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-54446-0_34.
Zheng, Zhi-Ming. "Human Papillomavirus (HPV)." In Encyclopedia of AIDS, 1–15. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9610-6_1-1.
Orbell, Sheina, Havah Schneider, Sabrina Esbitt, Jeffrey S. Gonzalez, Jeffrey S. Gonzalez, Erica Shreck, Abigail Batchelder, et al. "Human Papillomavirus (HPV)." In Encyclopedia of Behavioral Medicine, 1004–6. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_652.
Dudley, Matthew Z., Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O’Leary, and Saad B. Omer. "Human Papillomavirus (HPV)." In The Clinician’s Vaccine Safety Resource Guide, 61–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94694-8_10.
García, Luis I. "Human Papillomavirus (HPV)." In Encyclopedia of Behavioral Medicine, 1113–15. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_652.
Gooch, Jan W. "Human Papillomavirus (HPV)." In Encyclopedic Dictionary of Polymers, 899. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_13951.
Field, Nigel, and Richard Gilson. "Human Papillomavirus (HPV)." In Case Studies in Infection Control, 101–11. London; New York : Taylor & Francis Group, [2018]: Garland Science, 2018. http://dx.doi.org/10.1201/9780203733318-9.
Zheng, Zhi-Ming. "Human Papillomavirus (HPV)." In Encyclopedia of AIDS, 1028–41. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7101-5_1.
Lange, S., S. Son, M. Jensen, A. Medenblik, J. Sullivan, E. Basting, and G. Stuart. "HPV (Human Papillomavirus)." In Encyclopedia of Sexual Psychology and Behavior, 1–2. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-08956-5_1137-1.
Conference papers on the topic "Papillomavirus humain (HPV)":
Rocha, Willker Menezes da, Camila Freze Baez, Larissa Alves Afonso, Fernanda Nahoum Carestiato, Marianna Tavares Venceslau Gonçalves, Rafael Brandão Varella, and Silvia Maria Baeta Cavalcanti. "The use of DNA microarray assay as a diagnostic tool to study penile cancer associated with human papillomavirus." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p159.
Pereira, Igor Muzetti, and Vinícius Victor Lelis. "Developing a open-source serious game for control and education on HPV and Cervical Cancer." In Congresso Latino-Americano de Software Livre e Tecnologias Abertas. Sociedade Brasileira de Computação - SBC, 2019. http://dx.doi.org/10.5753/latinoware.2019.10344.
Herman, B. "APPLICATIONS OF LASER OPTICAL MICROSCOPIC TECHNIQUES IN DECIPHERING DISEASE SPECIFIC MECHANISMS AND DIAGNOSIS." In Biomedical Optical Spectroscopy and Diagnostics. Washington, D.C.: Optica Publishing Group, 2006. http://dx.doi.org/10.1364/bosd.1996.ft5.
Орлина, Маргарита Анатольевна, Дмитрий Павлович Вергилесов, Ксения Игоревна Батаева, and Дарья Сергеевна Латышева. "PREVENTION OF HPV INFECTIONS IN ADOLESCENT GIRLS." In Наука как пространство возможностей и развития: сборник статей международной научной конференции (Санкт-Петербург, Апрель 2024). Crossref, 2024. http://dx.doi.org/10.58351/240423.2024.77.79.002.
Suryani, I., and F. Adi-Kusumo. "Numerical simulation of a two-sex human papillomavirus (HPV) vaccination model." In SYMPOSIUM ON BIOMATHEMATICS (SYMOMATH 2013). AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4866544.
Katz, Mira Lynn, Paul L. Reiter, Mack T. Ruffin, and Electra D. Paskett. "Abstract A15: Development of a multilevel human papillomavirus (HPV) vaccine intervention." In Abstracts: Seventh AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 9-12, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7755.disp14-a15.
Gupta, Ishita, Ayesha Jabeen, Maria K. Smatti, Hamda A. Al-Thawadi, Gheyath K. Nasrallah, Ali A. Sultan, Moussa Al-Khalaf, Semir Vranic, and Ala-Eddin Al-Moustafa. "Co-Prevalence of Human Papillomavirus and Epstein Barr Virus in Healthy Blood Donors in Qatar." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0120.
Feijão, Maria Clara Tomaz, Fernanda Pimentel Arraes Maia, Eduarda Sousa Machado, Emanuel Cintra Austregésilo Bezerra, and Luiz Gonzaga Porto Pinheiro. "DERMOSCOPY OF THE PAPILLA TO THE IDENTIFICATION OF HUMAN PAPILLOMAVIRUS SIGNS IN TEN BREAST CANCER PATIENTS COMPARED TO TEN CONTROLS WITHOUT BREAST COMPLAINTS." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1023.
Smith, Laurie, Dirk Van Niekerk, Mel Krajden, Lovedeep Gondara, Darrel Cook, Marette Lee, Ruth Martin, et al. "O17.2 Women’s experiences with primary human papillomavirus (HPV) testing for cervix screening: HPV focal exit survey results." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.200.
Muhammad Afzal, Afifa. "The Moderating Effect of Beliefs on HPV Awareness and HPV Vaccination Acceptance among Female Patients in Islamabad City." In 2nd International Conference on Public Health and Well-being. iConferences (Pvt) Ltd, 2021. http://dx.doi.org/10.32789/publichealth.2021.1001.
Reports on the topic "Papillomavirus humain (HPV)":
van de Sande, Anna, Malika Kengsakul, Margot Koeneman, Marta Jozwiak, Cornelis Gerestein, Arnold-Jan Kruse, Edith van Esch, et al. Imiquimod in cervical dysplasia: a review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0046.
Li, Yanhui. Efficacy of non-invasive photodynamic therapy for female lower reproductive tract diseases associated with HPV infection: a comprehensive meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0092.